Joint supplements are among the most widely purchased companion animal health products, but evidence for their efficacy varies considerably between products. Understanding the science helps owners make welfare-informed purchasing decisions.
The joint supplement market for companion animals reflects both genuine welfare concern and commercial opportunity, in a regulatory environment that allows extensive health claims without the evidence standards required for licensed medicines. Many owners purchase supplements in good faith, motivated by real concern for arthritic pets, but make choices based on marketing rather than evidence. The welfare implications are significant in both directions: supplements with genuine efficacy may meaningfully reduce pain and improve quality of life in arthritic dogs; ineffective products waste resources that could be directed toward more impactful interventions and may create false reassurance that pain is being managed. The most impactful welfare interventions for arthritic dogs — weight management reducing load on painful joints, appropriate exercise maintaining muscle support without exacerbating inflammation, and veterinary pain assessment leading to appropriate multimodal medication — are less commercially visible than supplements but far more evidence-based. Supplements should complement, not substitute for, veterinary assessment and treatment.